Algernon Pharmaceuticals Stock Retained Earnings
| AGNPF Stock | USD 0.05 0 5.11% |
Algernon Pharmaceuticals fundamentals help investors to digest information that contributes to Algernon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Algernon OTC Stock. The fundamental analysis module provides a way to measure Algernon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Algernon Pharmaceuticals otc stock.
Algernon |
Algernon Pharmaceuticals OTC Stock Retained Earnings Analysis
Algernon Pharmaceuticals' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Algernon Pharmaceuticals has a Retained Earnings of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The retained earnings for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
Algernon Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.53 | |||
| Current Valuation | 3.03 M | |||
| Shares Outstanding | 2.41 M | |||
| Shares Owned By Insiders | 1.70 % | |||
| Shares Owned By Institutions | 14.73 % | |||
| Price To Book | 1.02 X | |||
| EBITDA | (6.02 M) | |||
| Net Income | (6.05 M) | |||
| Cash And Equivalents | 872.84 K | |||
| Cash Per Share | 0.44 X | |||
| Current Ratio | 1.16 X | |||
| Book Value Per Share | 1.86 X | |||
| Cash Flow From Operations | (2.91 M) | |||
| Earnings Per Share | (2.28) X | |||
| Beta | 0.32 | |||
| Market Capitalization | 3.96 M | |||
| Total Asset | 8.14 M | |||
| Net Asset | 8.14 M |
About Algernon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Algernon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Algernon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Algernon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Algernon OTC Stock
Algernon Pharmaceuticals financial ratios help investors to determine whether Algernon OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Algernon with respect to the benefits of owning Algernon Pharmaceuticals security.